Refining the therapeutic range of posaconazole and isavuconazole for efficient therapeutic drug monitoring using a bioassay approach.
Adult
Antifungal Agents
/ pharmacokinetics
Aspergillus fumigatus
/ drug effects
Biological Assay
/ methods
Candida parapsilosis
/ drug effects
Disk Diffusion Antimicrobial Tests
Drug Monitoring
/ methods
Female
Humans
Male
Middle Aged
Nitriles
/ pharmacokinetics
Pyridines
/ pharmacokinetics
Triazoles
/ pharmacokinetics
bioassay
isavuconazole
pharmacokinetic-pharmacodynamic
posaconazole
therapeutic drug monitoring
Journal
Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
02
05
2019
revised:
22
07
2019
accepted:
03
09
2019
pubmed:
11
9
2019
medline:
26
11
2020
entrez:
11
9
2019
Statut:
ppublish
Résumé
Therapeutic drug monitoring (TDM) of antifungal triazole was recommended, except for isavuconazole (ISA) whose target trough concentrations (C
Substances chimiques
Antifungal Agents
0
Nitriles
0
Pyridines
0
Triazoles
0
isavuconazole
60UTO373KE
posaconazole
6TK1G07BHZ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
279-287Informations de copyright
© 2019 Société Française de Pharmacologie et de Thérapeutique.
Références
Cornely O.A., Duarte R.F., Haider S. et al. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J. Antimicrob. Chemother. (2016) 71(3) 718-726.
Cornely O.A., Robertson M.N., Haider S. et al. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J. Antimicrob. Chemother. (2017) 72(12) 3406-3413.
Marty F.M., Ostrosky-Zeichner L., Cornely O.A. et al. Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis. Lancet Infect. Dis. (2016) 16(7) 828-837.
Maertens J.A., Raad I.I., Marr K.A. et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet (2016) 387(10020) 760-769.
Ullmann A.J., Aguado J.M., Arikan-Akdagli S. et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin. Microbiol. Infect. (2018) 24 e1-e38.
Durani U., Tosh P.K., Barreto J.N., Estes L.L., Jannetto P.J., Tande A.J. Retrospective comparison of posaconazole levels in patients taking the delayed-release tablet versus the oral suspension. Antimicrob. Agents Chemother. (2015) 59(8) 4914-4918.
Miceli M.H., Perissinotti A.J., Kauffman C.A., Couriel D.R. Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis. Mycoses (2015) 58(7) 432-436.
Cumpston A., Caddell R., Shillingburg A. et al. Superior serum concentrations with posaconazole delayed-release tablets compared to suspension formulation in hematological malignancies. Antimicrob. Agents Chemother. (2015) 59(8) 4424-4428.
Jeong W., Snell G.I., Levvey B.J. et al. Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations. J. Antimicrob. Chemother. (2018) 73(3) 748-756.
Launay M., Roux A., Beaumont L. et al. Posaconazole tablets in real-life lung transplantation: Impact on exposure, drug-drug interactions, and drug management in lung transplant patients, including those with cystic fibrosis. Antimicrob. Agents Chemother. (2018) 62(3) e02061-17.
Stelzer D., Weber A., Ihle F. et al. Posaconazole liquid vs tablet formulation in lung transplant recipients. Mycoses (2018) 61(3) 186-194.
Pettit N.N., Miceli M.H., Rivera C.G et al. Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation. J. Antimicrob. Chemother. (2017) 72(8) 2355-2358.
Jung D.S., Tverdek F.P., Kontoyiannis D.P. Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity. Antimicrob Agents Chemother. (2014) 58(11) 6993-6995.
Boglione-Kerrien C., Picard S., Tron C. et al. Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies. J. Cancer Res. Clin. Oncol. (2018) 144(1) 127-134.
Petitcollin A., Boglione-Kerrien C., Tron C. et al. Population pharmacokinetics of posaconazole tablets and monte carlo simulations to determine whether all patients should receive the same dose. Antimicrob. Agents Chemother. (2017) 61(11) e01166-17.
Kozuch J.M., Feist A., Yung G. et al. Low dose posaconazole delayed release tablets for fungal prophylaxis in lung transplant recipients. Clin. Transplant. (2018) 32(8) e13300.
Kovanda L.L., Kolamunnage-Dona R., Neely M., Maertens J., Lee M., Hope W.W. Pharmacodynamics of isavuconazole for invasive mold disease: role of galactomannan for real-time monitoring of therapeutic response. Clin. Infect. Dis. (2017) 64(11) 1557-1563.
Petraitis V., Petraitiene R., Moradi P.W. et al. Pharmacokinetics and concentration-dependent efficacy of isavuconazole for treatment of experimental invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. (2016) 60(5) 2718-2726.
Buil J.B., Brüggemann R.J.M., Wasmann R.E. et al. Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs. J. Antimicrob. Chemother. (2018) 73(1) 134-142.
Desai A.V., Kovanda L.L., Hope W.W. et al. Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi. Antimicrob Agents Chemother. (2017) 61(12) e01034-17
Kim T., Jancel T., Kumar P., Freeman A.F. Drug-drug interaction between isavuconazole and tacrolimus: a case report indicating the need for tacrolimus drug-level monitoring. J. Clin. Pharm. Ther. (2015) 40(5) 609-611.
Wu X., Clancy C.J., Rivosecchi R.M. et al. Pharmacokinetics of intravenous isavuconazole in solid-organ transplant recipients. Antimicrob. Agents Chemother. (2018) 62(12)e01643-18.
Tonini J., Bailly S., Gautier-Veyret E. et al. Contribution of a simple bioassay in effective therapeutic drug monitoring of posaconazole and voriconazole. Ther. Drug Monit. (2015) 37(5) 685-688.
Vyzantiadis T.-A., Yannaki E., Oliver D.A. et al. Alternative approaches to the therapeutic drug monitoring of prophylactic posaconazole in haematology patients. J. Mycol. Med. (2018) 28(1) 65-69.
Siopi M., Neroutsos E., Zisaki K. et al. Bioassay for determining voriconazole serum levels in patients receiving combination therapy with echinocandins. Antimicrob. Agents Chemother. (2016) 60(1) 632-636.
Cendejas-Bueno E., Forastiero A., Rodriguez-Tudela J.L., Cuenca-Estrella M., Gomez-Lopez A. HPLC/UV or bioassay: two valid methods for posaconazole quantification in human serum samples. Clin. Microbiol. Infect. (2012) 18(12) 1229-1235.
Jourdil J.-F., Tonini J., Stanke-Labesque F. Simultaneous quantitation of azole antifungals, antibiotics, imatinib, and raltegravir in human plasma by two-dimensional high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2013) 919-920 1-9.
Vanhee L.M.E., Symoens F., Nelis H.J., Coenye T..Microsatellite typing of Aspergillus fumigatus isolates recovered from deep organ samples of patients with invasive aspergillosis. Diagn. Microbiol. Infect. Dis. (2008) 62(1) 96-98.
Andes D., Kovanda L., Desai A., Kitt T., Zhao M., Walsh T.J. Isavuconazole concentration in real-world practice: consistency with results from clinical trials. Antimicrob. Agents Chemother. (2018) 62(7) e00585-18.
Lenczuk D., Zinke-Cerwenka W., Greinix H. et al. Antifungal prophylaxis with posaconazole delayed-release tablet and oral suspension in a real-life setting: plasma levels, efficacy, and tolerability. Antimicrob Agents Chemother. (2018) 62(6) e02655-17.
Tverdek F.P., Heo S.T., Aitken S.L., Granwehr B., Kontoyiannis D.P. Real-life assessment of the safety and effectiveness of the new tablet and intravenous formulations of posaconazole in the prophylaxis of invasive fungal infections via analysis of 343 courses. Antimicrob Agents Chemother. (2017) 61(8) e00188-17.
Foolad F., Kontoyiannis D.P. Persistent CNS toxicity in a patient receiving posaconazole tablets after discontinuation of voriconazole due to supratherapeutic serum levels. J Antimicrob Chemother. (2018) 73(1) 256-258.
Pfaller M.A., Rhomberg P.R., Wiederhold N.P., et al. Vitro activity of isavuconazole against opportunistic fungal pathogens from two mycology reference laboratories. Antimicrob. Agents Chemother. (2018) 62(10) e01230-18.
Marcos-Zambrano L.J., Gómez A., Sánchez-Carrillo C. et al. Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect. Clin. Microbiol. Infect. (2018) 24(12) 1343.e1-1343.e4.
Pfaller M.A., Rhomberg P.R., Castanheira M. Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds. Diagn. Microbiol. Infect. Dis. (2018) 92(1) 43-45.
Darnaud L., Lamoureux F., Godet C. et al. Isavuconazole kinetic exploration for clinical practice. Drugs R D. (2018) 18(4) 317-321.
Merck Sharp & Dohme Limited. Noxafil (posaconazole) oral suspension, summary of product characteristics. Merck Sharp & Dohme, Hertfordshire, (2012).
Schmitt-Hoffmann A., Roos B., Maares J. et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob. Agents Chemother. (2006) 50(1) 286-293.